title: Bilateral primary renal lymphoma in a pediatric patient: staging and response evaluation with ¹⁸F-FDG PET/CT.
abstract: Primary renal lymphoma (PRL) is a rare disease. We here present the case of an 8-year-old child who presented with bilateral renal masses. On biopsy, it was confirmed to be B-cell non-Hodgkin's lymphoma. (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET/CT) for staging demonstrated (18)F-FDG avid bilateral renal masses, with no other abnormal focus. Follow up (18)F-FDG PET/CT showed complete resolution of the disease after six cycles of chemotherapy. Here we have highlighted the potential role of (18)F-FDG PET/CT in staging and response evaluation of a patient with PRL and presented a brief review.
authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
authors: V S
authors: VS
authors: Dhull
authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
authors: A
authors: A
authors: Mukherjee
authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
authors: S
authors: S
authors: Karunanithi
authors: Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
authors: P
authors: P
authors: Durgapal
authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
authors: C
authors: C
authors: Bal
authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Electronic address: rkphulia@yahoo.com.
authors: R
authors: R
authors: Kumar
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage; D019275:Radiopharmaceuticals; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: (18)F-FDG; Evaluación de la respuesta; Linfoma renal primario; PET/CT; PET/TAC; Primary renal lymphoma; Response evaluation